CME Group
CME
$0.00
-2.89%
CME Group Inc. is a global financial marketplace operator, providing a platform for trading futures and derivatives across asset classes including interest rates, equity indexes, foreign exchange, energy, metals, and agricultural commodities. It is the world's leading and most diverse derivatives marketplace, a position solidified through strategic acquisitions like CBOT, NYMEX, and NEX, and holds a significant stake in S&P Dow Jones Indexes. The current investor narrative centers on its role as a critical financial infrastructure play, with attention driven by its performance amid persistent market volatility and high interest rates, which boost trading volumes in its core interest rate and equity index products, as evidenced by recent dividend increases and strong cash flow generation.…
CME
CME Group
$0.00
Related headlines
Investment Opinion: Should I buy CME Today?
Rating: Hold. The core thesis is that CME is a high-quality, defensive financial infrastructure asset trading at a full valuation, offering limited near-term upside but substantial downside protection, making it suitable for risk-averse portfolios seeking stability and income.
Supporting evidence includes a forward PE of 22.2x, which is lower than the trailing 24.3x but still represents a premium valuation. Revenue growth is steady at 8.1% YoY, and profitability is exceptional with net margins of 62.0%. The stock offers a 12.2% implied upside to the average analyst target of ~$322.80, but this is tempered by a high payout ratio of 97.2% and a dividend yield of only 4.0%. The company's immense liquidity (current ratio of 93.0) and low debt provide a solid foundation.
The thesis would upgrade to a Buy if the forward PE compressed below 20x (offering a more attractive entry point) or if revenue growth accelerated sustainably above 10% YoY. It would downgrade to a Sell if trading volumes collapsed, causing a sequential decline in revenue, or if the net margin contracted significantly below 55%. Relative to its history and peers, CME is fairly valued to slightly overvalued, with the market paying a premium for its quality and defensive characteristics.
Sign up to view all
CME 12-Month Price Forecast
CME presents a high-quality hold. Its unmatched profitability and defensive characteristics justify a valuation premium, but that same premium caps near-term upside and introduces sensitivity to earnings momentum. The most likely 12-month outcome is range-bound trading around the $315 level as the stock digests its recent gains. The stance would upgrade to Bullish on a meaningful pullback towards $270 (offering a better risk/reward entry) or clear evidence of accelerating volume growth. It would turn Bearish if the technical breakdown below $252 support occurs, signaling a fundamental deterioration in its volume outlook.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on CME Group's 12-month outlook, with a consensus price target around $0.00 and implied upside of — versus the current price.
Average Target
$0.00
7 analysts
Implied Upside
—
vs. current price
Analyst Count
7
covering this stock
Price Range
$0 - $0
Analyst target range
CME is covered by 6 analysts, indicating moderate institutional coverage. The consensus sentiment leans neutral to slightly bullish, with recent institutional ratings showing a mix of Overweight/Buy (Morgan Stanley, TD Cowen), Equal Weight/Hold (Barclays, Argus Research, RBC Capital), and one Underweight (JP Morgan). The average target price implied by estimated EPS and the forward PE is approximately $322.80 (14.55 EPS * 22.19 forward PE), suggesting an implied upside of about 12.2% from the current price of $287.65. The target range, derived from estimated EPS, spans from a low of ~$307 (13.83 EPS * 22.19 PE) to a high of ~$343 (15.45 EPS * 22.19 PE). The high target assumes successful execution on growth initiatives and sustained high trading volumes, while the low target likely factors in potential cyclical downturns in trading activity or margin compression. The recent pattern of ratings includes a notable downgrade from Argus Research (Buy to Hold) in March 2026, which may signal growing caution among some analysts following the stock's strong run, contributing to the observed short-term price weakness.
Bulls vs Bears: CME Investment Factors
The evidence currently tilts slightly bullish, primarily due to CME's exceptional financial quality, defensive cash flows, and implied upside to analyst targets. However, the bear case is strengthened by the stock's premium valuation and recent technical weakness. The single most important tension in the investment debate is whether CME's premium valuation (24.3x trailing PE) is justified by its defensive, high-margin business model and growth trajectory, or if it represents a vulnerability that will lead to compression if earnings growth decelerates or market sentiment shifts away from defensive plays.
Bullish
- Exceptional Profitability & Operating Leverage: CME's Q4 2025 net margin expanded to 62.0%, up from 57.4% a year ago, demonstrating significant operating leverage. This is driven by an asset-light model with an 85.4% gross margin, allowing revenue growth to flow efficiently to the bottom line.
- Fortress Balance Sheet & Strong Cash Flow: The company has a debt-to-equity ratio of just 0.13 and a current ratio of 93.0, indicating immense liquidity and minimal financial risk. It generated $4.19 billion in TTM free cash flow, funding substantial shareholder returns, including a recent $4 billion total payout.
- Defensive Business Model in Volatile Markets: CME's low beta of 0.296 shows it is roughly 70% less volatile than the broader market, acting as a defensive holding. Its core interest rate and equity index products see elevated demand during periods of uncertainty and high rates, supporting revenue growth of 8.1% YoY in Q4.
- Analyst Target Implies Significant Upside: The implied average analyst target price is approximately $322.80, representing a 12.2% upside from the current price of $287.65. This target is based on a forward PE of 22.2x and estimated EPS of $14.55, suggesting the market has not fully priced in expected earnings.
Bearish
- Premium Valuation Limits Multiple Expansion: CME trades at a trailing PE of 24.3x, which is above its own historical range and commands a premium to typical financial data & exchange peers. This leaves little room for valuation expansion and increases sensitivity to any earnings disappointment.
- Recent Price Weakness & Analyst Caution: The stock has pulled back -6.88% over the past month, underperforming the SPY by over 14 percentage points. This coincides with a notable analyst downgrade from Argus Research (Buy to Hold) in March 2026, signaling growing caution after a strong run.
- Cyclical Exposure to Trading Volumes: Revenue is directly tied to trading activity, which is cyclical and sensitive to macroeconomic conditions. A shift to a lower-volatility, lower-rate environment could reduce volumes in its key interest rate and equity index products, pressuring top-line growth.
- High Payout Ratio Limits Reinvestment: The dividend payout ratio is 97.2%, indicating nearly all earnings are returned to shareholders. While attractive for income, this leaves minimal retained earnings for internal reinvestment in growth, making the company reliant on debt or cash reserves for major initiatives.
CME Technical Analysis
The stock is in a sustained uptrend over the past year, evidenced by a 1-year price change of +9.57%. Currently trading at $287.65, it sits approximately 46% above its 52-week low of $251.9 and about 13% below its 52-week high of $329.16, indicating it is in the upper-mid range of its yearly band, suggesting momentum but with room before testing recent highs. Recent momentum shows a divergence, with a strong 3-month gain of +2.92% but a sharp 1-month pullback of -6.88%, indicating short-term profit-taking or a consolidation phase after the rally that peaked in early March around $326. This divergence suggests a potential cooling period or a healthy correction within the broader uptrend. Key technical support is anchored at the 52-week low of $251.9, while immediate resistance is at the recent 52-week high of $329.16. A decisive breakout above $329 would signal a resumption of the primary bull trend, whereas a breakdown below the $252 level would invalidate the uptrend and suggest deeper correction risks. The stock exhibits low market-relative volatility with a beta of 0.296, meaning it is roughly 70% less volatile than the broader market (SPY), which is characteristic of a defensive, cash-generative business model and influences position sizing for risk-averse portfolios.
Beta
0.30
0.30x market volatility
Max Drawdown
-11.9%
Largest decline past year
52-Week Range
$252-$329
Price range past year
Annual Return
+9.6%
Cumulative gain past year
| Period | CME Return | S&P 500 |
|---|---|---|
| 1m | -6.9% | +9.5% |
| 3m | +2.9% | +2.7% |
| 6m | +7.4% | +5.8% |
| 1y | +9.6% | +34.9% |
| ytd | +6.7% | +4.1% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
CME Fundamental Analysis
CME's revenue trajectory shows steady growth, with Q4 2025 revenue of $1.65 billion representing an 8.1% year-over-year increase. The multi-quarter trend reveals consistent top-line expansion, with revenue growing from $1.49 billion in Q1 2024 to the latest $1.65 billion, driven by its core clearing and transaction fees, which contributed $1.33 billion in the most recent period. This growth is underpinned by robust trading volumes in interest rate and equity index derivatives, aligning with the current macroeconomic environment. The company is highly profitable, with Q4 2025 net income of $1.17 billion and a net margin of 62.0%. Gross margins are exceptionally high at 85.4% for the quarter, consistent with its asset-light exchange model. Profitability has been expanding, as evidenced by the net margin improving from 57.4% in Q4 2024 to the current 62.0%, demonstrating significant operating leverage and pricing power within its monopolistic market structure. CME possesses a fortress balance sheet with minimal financial risk, evidenced by a low debt-to-equity ratio of 0.13 and a staggering current ratio of 93.0, indicating immense liquidity. The company generates substantial cash, with trailing twelve-month free cash flow of $4.19 billion, providing ample internal funding for dividends, share buybacks, and strategic initiatives without reliance on external financing, which is reflected in its high ROE of 14.1%.
Quarterly Revenue
$1.6B
2025-12
Revenue YoY Growth
+0.08%
YoY Comparison
Gross Margin
+0.85%
Latest Quarter
Free Cash Flow
$4.2B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is CME Overvalued?
Given CME's substantial net income of $1.17 billion, the primary valuation metric is the Price-to-Earnings (PE) ratio. The stock trades at a trailing PE of 24.3x and a forward PE of 22.2x. The forward multiple being lower than the trailing multiple suggests the market anticipates modest earnings growth, with the forward estimate implying a compression in the earnings multiple. Compared to sector averages, CME's valuation commands a significant premium. Its trailing PE of 24.3x is above typical financial data & exchange peers, though a direct industry average from the provided data is not available for precise quantification. This premium is likely justified by its market-leading position, high-margin business model, and defensive cash flow characteristics, which are prized during periods of economic uncertainty. Historically, the stock's current trailing PE of 24.3x sits above its own multi-year range observed in the historical ratios data, which has often fluctuated between the high teens and low 20s. Trading near the upper end of its historical valuation band suggests the market is pricing in optimistic expectations for sustained earnings and dividend growth, leaving limited room for multiple expansion and increasing sensitivity to any earnings disappointment.
PE
24.3x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 19x~37x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
17.1x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks are minimal but not zero. CME's primary financial risk is its dependence on sustained trading volumes for revenue growth, as a cyclical downturn could pressure the 8.1% YoY growth rate. The high payout ratio of 97.2% also limits financial flexibility for large-scale reinvestment, though this is mitigated by a massive $4.19B TTM free cash flow and a fortress balance sheet with a 0.13 debt-to-equity ratio. Earnings volatility is a risk, though the expanding net margin to 62.0% shows improving cost control.
Market & Competitive Risks center on valuation and macro sensitivity. Trading at a trailing PE of 24.3x, above its historical range, the stock faces compression risk if growth expectations moderate or if investor sentiment rotates away from premium-priced defensive stocks. Its low beta of 0.296, while defensive, also means it may lag in strong bull markets, as evidenced by its 25-percentage-point underperformance versus the SPY over the past year. Regulatory changes impacting derivatives trading pose a persistent, though low-probability, threat to its monopolistic market structure.
Worst-Case Scenario involves a sharp decline in macroeconomic volatility and a rapid normalization of interest rates, leading to a sustained drop in trading volumes across CME's core products. This could trigger earnings misses, multiple compression from its elevated PE, and a re-rating towards a more cyclical valuation. The realistic downside could see the stock retreat to its 52-week low of $251.9, representing a potential loss of approximately -12.4% from the current price of $287.65. A more severe bear case, incorporating analyst low targets, suggests a floor near $307, but a break below key support could see a drawdown approaching the -11.9% max drawdown recently observed.
FAQ
The key risks are, in order of severity: 1) Valuation Risk: Trading at a premium PE of 24.3x, the stock is vulnerable to multiple compression if growth slows. 2) Cyclical Revenue Risk: Earnings are tied to trading volumes, which can decline in calm or falling rate markets. 3) Competitive/Regulatory Risk: Though low-probability, changes in derivatives regulation or new competitive threats could impact its moat. 4) Capital Allocation Risk: A 97% payout ratio limits internal reinvestment for growth, though massive FCF mitigates this. The low beta of 0.296 significantly reduces market-related risk.
The 12-month forecast presents three scenarios. The Base Case (60% probability) targets $307-$323, assuming steady volumes and CME meeting its $14.55 EPS estimate. The Bull Case (25%) targets $329-$343, driven by heightened volatility and earnings beats. The Bear Case (15%) targets $252-$307, triggered by a volume slump and multiple compression. The Base Case is most likely, anchored on CME's defensive cash flows meeting current expectations. The key assumption is that the macroeconomic environment for trading (interest rates, volatility) remains supportive but not spectacular.
CME is fairly valued to slightly overvalued. Its trailing PE of 24.3x is above its own historical range and represents a premium to typical financial exchange peers, justified by its 62% net margin, defensive profile (beta 0.296), and market-leading position. The forward PE of 22.2x suggests the market anticipates modest earnings growth. This valuation implies the market is paying up for quality and stability, leaving limited room for multiple expansion. Compared to its growth rate (8.1% revenue YoY) and a PEG ratio of 1.58, the stock is not egregiously expensive but is fully priced.
CME is a good buy for risk-averse investors seeking a defensive, high-quality holding with reliable cash generation, but it is less attractive for those seeking high growth or deep value. The stock offers a 12.2% implied upside to the average analyst target of ~$322.80, but this potential return is moderated by its premium valuation at a 24.3x trailing PE. The biggest downside risk is multiple compression if trading volumes decline. Therefore, it is a good buy for patient, income-oriented investors at a slightly lower entry point, but at current levels, it is fairly valued and warrants a Hold rating.
CME is best suited for long-term investment as a core defensive holding. Its business model benefits from long-term growth in global derivatives markets, and its high cash flow supports reliable dividend growth. The low beta of 0.296 makes it a poor candidate for short-term trading based on market momentum, as it typically exhibits lower volatility. Given its full valuation, short-term traders might find better opportunities elsewhere. A minimum holding period of 3-5 years is suggested to ride out cyclical volume fluctuations and benefit from the compounding effect of its capital returns.
